Spots Global Cancer Trial Database for 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Official Title: 64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer
Study ID: NCT05407311
Interventions
Study Description
Brief Summary: The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Tower Urology, Los Angeles, California, United States
Stanford University, Stanford, California, United States
Biogenix Molecular, Miami, Florida, United States
Bamf Health, Inc, Grand Rapids, Michigan, United States
St Louis University Hospital, Saint Louis, Missouri, United States
GU Research Network, Omaha, Nebraska, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Urology San Antonio, San Antonio, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
